Revenue, 2025

USD 20.84 Billion

Forecast, 2035

USD 58.64 Billion

CAGR, 2026-2035

10.9%

Report Coverage

Global

Biologics CDMO for mAB Market Trends for 2026

The global biologics CDMO for mAB market size is calculated at USD 20.84 billion in 2025, driven by increasing demand for targeted therapies. The market continues to grow in 2026 at USD 23.11 billion due to the expanding manufacturing capabilities, high healthcare investments, and expanding advanced therapies. It is expected to reach USD 58.64 billion by 2035 as a rise in demand for end-to-end services, expanding manufacturing networks, and growing ADC advancements accelerate market expansion. The market is expected to grow at a CAGR of 10.9% during the forecasted year 2026-2035. North America accounted for 43% of the market in 2025 due to a robust biologics innovation ecosystem, large CDMOs, and high R&D spending.

Biologics CDMO for mAB Market Key Takeaways

• Biologics CDMO for mAB sector push the market to USD 23.11 billion by 2026.
• Long-term projections show USD 58.64 billion valuation by 2035.
• Growth is expected at a steady CAGR of 10.9% in between 2026 to 2035.
• North America held the major revenue share of 43% in the global biologics CDMO for mAB market in 2025.
• Asia Pacific held a 21% share of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By service type, the GMP manufacturing segment held a dominant revenue share of 41% of the market in 2025. 
• By service type, the fill-finish services segment held 8% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period. the growth.
• By molecule type, the conventional monoclonal antibodies segment held a dominant revenue share of 63% of the market in 2025.
• By molecule type, the bispecific monoclonal antibodies segment held 21% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By expression system type, the CHO cells segment held a dominant revenue share of 81% of the market in 2025.
• By expression system type, the HEK293 cells segment held 6% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By manufacturing scale type, the commercial scale segment held a dominant revenue share of 54% of the market in 2025.
• By manufacturing scale type, the clinical scale segment held 34% of the market in 2025 and is expected to grow at the fastest CAGR of 11.8% during the forecast period.
• By production stage type, the drug substance manufacturing segment held a dominant revenue share of 67% of the market in 2025.
• By production stage type, the drug product manufacturing segment held 33% of market share in 2025 and is expected to grow at the fastest CAGR of 11.6% during the forecast period.
• By end user, the large biopharmaceutical companies segment held a dominant position in the market with a share of 48% in 2025.
• By end user, the emerging biotech companies segment held 34% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By indication type, the oncology segment held a dominant revenue share of 46% of the market in 2025.
• By indication type, the infectious diseases segment held 8% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.

What are the Biologics CDMO for mAB?

The biologics CDMO for mAB refers to the contract development and manufacturing organizations offering outsourcing services for the development and production of monoclonal antibodies. It offers a wide range of services and models such as end-to-end, one-stop shop, development-to-commercialization, and platform-based manufacturing, which support services like cell line development, process development, clinical manufacturing, analytical testing, and commercial production.

Evolution of Biologics CDMO Services

The growth in technical complexity, scale-up challenges, lack of expertise, and regulatory barriers among companies increased the dependence on biologics CDMOs, increasing new collaborations. At the same time, their limited global reach and integrated clinical services hampered their use, which fueled their advancement. According to the report by Payl Rabde, this increased their interest in enhancing manufacturing capability and integration, which promoted their rapid expansion.

Importance of mAb Manufacturing Outsourcing

Molecule complexity, need for flexible manufacturing services, and changing regulatory requirements are increasing the demand for comprehensive manufacturing services. Additionally, cost constraints and evolving patient demand are also increasing the shift towards outsourced services.

Current Industry Landscape

Growing strategic importance of contract manufacturing, capacity utilization, and industry transformation are increasing the use of biologics CDMO for mAB. The growing demand for targeted therapies, expanding outsourcing services, and growing complex biologic pipelines are also driving the market expansion.

Market Trends

Growth of End-to-End CDMO Service Models

Integrated development and manufacturing services are becoming preferred, as they help in reducing development timelines. They also enhance project management and cost efficiency, which drives their demand.

Expansion of High-Capacity Manufacturing Facilities

Increasing investments in large-scale biologics production plants are expanding high-capacity manufacturing facilities. This promotes mAB production, large-scale manufacturing, and operational efficiency, driving their use.

Increasing Demand for Flexible Manufacturing Platforms

Growing adoption of modular facilities and multi-product manufacturing are expanding flexible manufacturing platforms, encouraging their use. They support varying products, commercial manufacturing, and reduce turnover time as well.

Rising Adoption of Digital Manufacturing Technologies

A rise in the use of automation, AI-assisted process monitoring, and smart manufacturing are attracting clients. They help in improving manufacturing efficiency, reducing production errors, and offers data drive decision which drives their adoption rates.

Expansion of Global Manufacturing Networks

Increasing regional diversification strategies among major CDMOs are expanding global manufacturing networks. They help in enhancing access to biologics CDMO services and strategic supply chain networks.

Market Dynamics

Market Drivers

The growing biologics approvals and advanced therapeutics pipeline are increasing the dependence on biologics CDMOs for mAB. The rise in outsourcing demand and growing manufacturing complexities are also some of the major market drivers.

Market Restraints

High capital investment, regulatory complexity, skilled workforce shortages, and production risks are the key market restraints.

Market Opportunities

A rise in ADC manufacturing and bispecific antibody advancements are creating new opportunities for market expansion, based on the survey conducted by Payal Rabde. Similarly, growing integrated service offerings and emerging markets are also opening new doors.

Market Challenges

The major market challenges encompass capacity balancing, supply chain disruptions, quality compliance, and cost pressures.

Impact of Macroeconomic Factors on the Market

Interest Rates and Capital Availability

High interest rates limit capacity expansion, while lower intertest promotes their expansion. Strong capital availability leads to CDMO expansion, whereas reduced capital availably slow down the process.

Inflation Impact on Manufacturing Costs

It increases the cost associated with raw materials, equipment, and production, reducing CDMO profit margins.

Geopolitical Risks and Supply Chain Diversification

Geopolitical tension drives supply chain uncertainty, encouraging dependence on localized supply chain networks and driving new investments.

Global Healthcare Spending Trends

Growing healthcare expenditure supports the adoption of various biologic therapies, promoting the use of biologics CDMOs for mAB development.

Industry Ecosystem Analysis

Raw Material Suppliers

Raw material suppliers for biologics CDMOs for mAB involve suppliers offering cell culture media, purification resins, sterile filtration systems, feeds, and single-use bioreactor bags.

Cell Line Technology Providers

Cell line technology providers of biologics CDMOs for mAB encompass stable mammalian host cell platforms, optimization tools, and advanced expression vectors.

Equipment Manufacturers

Equipment manufacturers of biologics CDMOs for mAB offer software systems and automated, cGMP-compliant bioprocessing hardware.

Single-Use Technology Suppliers

Single-use technology suppliers of biologics CDMOs for mAB provide tubing assemblies, plastic bioreactor bags, filtration modules, and connectors.

Analytical Service Providers

Analytical service providers of biologics CDMOs for mAB support molecular characterization, stability profile, and purity testing.

CDMOs

CDMOs drive end-to-end process development, cGMP-compliant manufacturing, and scale-up services, which increases their use.

Pharmaceutical & Biotechnology Clients

Pharmaceutical & biotechnology clients require manufacturing facilities along with technical and regulatory support for mAB production, which increases their reliance on biologics CDMOs.

Regulatory Agencies

Regulatory agencies promote the use of biologics CDMOs for mAB due to their standardized facilities, expertise, and strong quality control systems.

Value Chain Analysis

Research & Cell Line Development

• Research & cell line development of biologics CDMOs for mAB focuses on optimization of scalable upstream and downstream processes.
• Key players: Catalent, Abzena.

Process Development

• Process development of biologics CDMOs for mAB helps in ensuring contamination-free scalability.
• Key players: Fujifilm Diosynth Biotechnologies, Mabion.

GMP Manufacturing

• GMP manufacturing of biologics CDMOs for mAB focuses on maintaining sterility during the development of drug products with the use of bioreactors.
• Key players: Lonza, Samsung Biologics.

Fill-Finish Operations

• Fill-finish operations of biologics CDMOs for mAB focus on maintaining the product's safety and purity.
• Key players: Thermo Fisher Scientific, Vetter Pharma

Quality Testing

• Quality testing in biologics CDMOs for mAB drives the use of mass spectrometry, ELISA, and HPLC tools.
• Key players: Wuxi Biologics, 53Biologics.

Packaging & Distribution

• Packaging & Distribution services of biologics CDMOs for mAB offer automated serialization, labelling, and cold chain storage docks.
• Key players: Almac Group, PCI Pharma Services

Commercial Supply Management

• Commercial Supply Management of biologics CDMOs for mAB depends on large-scale global logistics and cGMP-compliant distribution networks.
• Key players: Boehringer Ingelheim.

Manufacturing Process Intelligence

Upstream Manufacturing Technologies

Upstream manufacturing technologies in biologics CDMOs for mAB encompass mammalian cell culture platforms, bioreactor systems, process analytical technologies, and continuous perfusion systems.

Downstream Purification Technologies

Downstream purification technologies in biologics CDMOs for mAB include protein A affinity chromatography, ion exchange chromatography, viral clearance technologies, and tangential flow filtration systems.

Fill-Finish Manufacturing Workflow

Fill-finish manufacturing workflow in biologics CDMOs for mAB offer services for aseptic formulation, syringe encapsulation, and leak detection.

Analytical Testing and Quality Assurance

Analytical testing and quality assurance services such as molecular characterization, purity profiling, stability testing, and batch releases are provided in biologics CDMOs for mAB.

Technology Transfer Process

The technology transfer process in biologics CDMOs for mAB focuses on risk assessment, analytical method validation, scale-up protocols, and validation batches.

Capacity Utilization and Manufacturing Infrastructure Analysis

Current Manufacturing Capacity

Current manufacturing capacity in biologics CDMOs for mAB is expanding due to a surge in the biologics pipeline, high demand for antibody drug conjugates, and a shift towards sterile fill-finish operations.

Capacity Expansion Projects

Capacity expansion projects in biologics CDMOs for mAB market are driven by growing demand for agile facilities, expanding commercial industries, and increasing investments.

Regional Capacity Distribution

Regional capacity distribution in biologics CDMOs for mAB is expanding due to growing demand for enhanced supply chain security and increasing manufacturing hubs.

Capacity Constraints and Bottlenecks

Capacity constraints and bottlenecks in biologics CDMOs for mAB encompass a shortage of sterile fill-finish lines and single-use assemblies.

Technology Landscape and Innovation Analysis

• Continuous Bioprocessing: It helps in accelerating the manufacturing process and boosts productivity.
• Single-Use Bioreactor Technologies: It helps in eliminating the need for cleaning and sterilization, and reduces contamination risks.
• Automation in Biologics Manufacturing: It reduces dependence on human intervention and the chances of operational errors and batch variability.
• Digital Twins and Smart Manufacturing: It helps in predicting outcomes and accelerates early-stage development and the tech transfer process.
• Advanced Process Analytics: It helps in real-time tracking, ensuring stringent quality and process control.
• AI Applications in Process Optimization: It helps in massive dataset analysis, identification of high-yielding cell clones, predictive equipment maintenance, and optimization of complex formulation development.

Regulatory and Compliance Landscape

• FDA Requirements: It encompasses strict adherence to 21 CFR regulations, precise documentation, electronic facility registration, and submission of clinical data.
• EMA Requirements: It includes adherence to the GMP guidelines, cell banking, purification, data-driven verification, and drug safety analysis.
• PMDA Regulations: It focuses on standards for biological ingredients, safety assessment, insoluble matter testing, and on-site inspections.
• NMPA Guidelines: It highlights joint client-CDMO oversight rules, risk-based supplier classification, equipment lifecycle documentation, and audit trails.
• GMP Compliance Standards: They are driven by system validation, stability control testing, cross-contamination validation, and cleanroom environmental control.
• Quality Risk Management: It focuses on critical parameter identification, risk control, and lifecycle risk review.

Pricing Analysis

Cell Line Development Pricing

Cell line development pricing depends on cell line complexity, development timeline, analytical testing needs, technology platforms, and regulatory requirements.

Process Development Costs

Process development costs are influenced by process complexity, analytical testing, development timelines, optimization requirements, and scale activities.

GMP Manufacturing Pricing

GMP manufacturing pricing is driven by production scale, facility utilization, batch size, raw materials, labor requirements, cell culture technology, and regulatory requirements.

Fill-Finish Pricing

Fill-finish pricing is determined by batch size, quality control testing, filling volume, sterility requirements, and packaging needs.

Factors Affecting CDMO Pricing

Factors affecting CDMO pricing are project complexities, production scale, manufacturing capacity, contract duration, technologies, and regulatory compliance.

Demand Analysis

Clinical Pipeline Demand

Expanding mAB clinical trials and increasing demand for biologics are increasing the outsourcing trends, driving the dependence on biologics CDMO services.

Commercial Manufacturing Demand

A rise in mAB therapies approvals and adoption of various biologic products are also fueling the outsourcing to CDMOs for large-scale manufacturing facilities.

Demand by Therapeutic Area

Growing chronic disease burden, demand for targeted therapies, and expanding applications are increasing the demand for biologics CDMO for mAB.

Demand by Company Size

The small and emerging biotech firms are relying on biologics CDMOs for faster product development, while large industries support their use for manufacturing flexibility and reduced overall cost.

Regional Demand Comparison

Increasing demand for targeted therapies, growing biologics pipelines, and healthcare investments are increasing the dependence on biologics CDMO services.

Customer Purchasing Behavior

Vendor Selection Criteria

Vendor selection criteria depend on manufacturing capacity, scalability, GMP compliance, quality assurance, and cost-effectiveness.

Outsourcing Decision Factors

Outsourcing decision factors encompass faster development timelines, limited in-house manufacturing capabilities, specialized technologies, and regulatory expertise.

Contract Duration Trends

Contract duration trends are driven by development timelines, manufacturing capacity, product commercialization success, technology transfer complexity, pricing agreements, and regulatory approvals.

Long-Term Strategic Partnerships

Consistent product quality, manufacturing capacity expansion, advanced technologies, supply chain support, and regulatory compliance drive long-term strategic partnerships.

Client Expectations from CDMOs

Client expectations from CDMOs include high-quality manufacturing, technical expertise, end-to-end services, flexible manufacturing, and transparency.

Investment and Funding Landscape

Venture Capital Investments

The venture capital investments support outsourcing trends and accelerate R&D and clinical pipeline growth.

Private Equity Activity

Private equity activity supports new collaborations and acquisitions, promoting manufacturing and operational capabilities.

Manufacturing Facility Investments

Manufacturing facility investments promote the expansion of mAb manufacturing and biologics production, increasing their dependence on biologics CDMOs.

Government Incentives

Growing government incentives drive R&D activities, innovations, technology adoption, and facility expansion.

Strategic Expansion Funding

Strategic expansion funding propels the development of new facilities, technology upgrades, and solidifies end-to-end services.

Mergers, Acquisitions, Partnerships, and Strategic Collaborations

Major Acquisitions

The major acquisitions in the biologics CDMO for mAB market encompass acquisitions of specialized biologics, fill-finish manufacturing facilities, advanced technologies, and biologics manufacturing facilities.

Capacity Expansion Partnerships

Capacity expansion partnerships in the market are driven by collaboration between biopharmaceutical companies and CDMOs, investments in new facilities, and demand for large-scale mAB production.

Technology Licensing Agreements

The technology licensing agreements help in enhancing access to advanced technology such as proprietary manufacturing platforms, bioprocessing technologies, and cell line technologies.

Long-Term Manufacturing Agreements

Collaboration between companies and CDMOs to leverage stable manufacturing capabilities, commercial-scale production, and supply chain security drives long-term manufacturing agreements.

Competitive Benchmarking Analysis

Manufacturing Capacity Comparison

Samsung Biologics, Lonza Group, and Wuxi Biologics dominated the biologics CDMO for mAB market depending on their manufacturing capacity.

Geographic Presence

Based on geographical presence, Lonza Group, Thermo Fisher Scientific, and Wuxi Biologics led the market.

Technology Capabilities

According to Payal Rabde's analysis, Wuxi Biologics, Fujifilm Diosynth Biotechnologies, and Samsung Biologics were the leaders in technology capabilities.

Service Portfolio Comparison

Lonza Group, Catalent, and Boehringer Ingelheim majorly contributed to the market expansion depending on their service portfolio.

Client Portfolio Analysis

By client portfolio analysis, Samsung Biologics, Lonza Group, and Wuxi Biologics were the top market players.

Quick Facts Table

Segmental Insights

By Service Type Insights

The GMP Manufacturing Segment Dominated the Market With 41% in 2025

The GMP manufacturing segment led the biologics CDMO for mAB market with 41% share in 2025, as clinical and commercial mAb production required specialized GMP infrastructure. Additionally, as per the analysis by Payal Rabde, capacity shortages also encouraged outsourcing, which increased their use. Large-scale biologics investments also sustained their demand.

The fill-finish services segment held a share of 8% of the market in 2025 and is expected to witness the fastest growth during the forecast period, due to rising commercialization of injectable biologics boosting aseptic filling demand. Prefilled formats are gaining popularity. Regulatory expectations are also increasing outsourcing.

By Molecule Type Insights

The Conventional Monoclonal Antibodies Segment Dominated the Market With 63% in 2025

The conventional monoclonal antibodies segment accounted for the highest revenue share of 63% of the biologics CDMO for mAB market in 2025, driven by numerous approved blockbuster antibodies, which required continuous manufacturing. Biosimilar expansion also supported production demand. Established manufacturing platforms also reduced risk.

The bispecific monoclonal antibodies segment held the second-largest share of 21% of the market in 2025 and is expected to show the highest growth during the forecast period, due to rapid clinical pipeline expansion accelerating outsourcing. Manufacturing complexity also favors experienced CDMOs. Oncology innovations also fuel investments.

By Expression System Insights

The CHO Cells Segment Dominated the Market With 81% in 2025

The CHO cells segment held a major revenue share of 81% of the biologics CDMO for mAB market in 2025, as CHO remained the preferred platform for therapeutic antibodies. High productivity and regulatory familiarity also supported their adoption. Continuous process improvements also enhanced efficiency.

The HEK293 cells segment held a share of 6% of the market in 2025 and is expected to expand rapidly during the forecast period, driven by the rising development of complex biologics, which expands HEK293 utilization. Improved transient expression technologies also accelerate research. Flexible production also supports their innovations.

By Manufacturing Scale Insights

The Commercial Scale Segment Dominated the Market With 54% in 2025

The commercial scale segment contributed the biggest revenue share of 54% of the biologics CDMO for mAB market in 2025, driven by growth in approved antibodies, which required consistent large-volume production. Capacity expansion by CDMOs also attracted major pharmaceutical companies. Long-term supply agreements also stabilized their demand.

The clinical scale segment held the second-largest share of 34% of the market in 2025 and is expected to gain the highest share with a CAGR of 11.8% during the forecast period, due to growing clinical trial activity, which increases GMP manufacturing requirements. More biologics enter Phase II and III studies, driving their demand. Flexible production capacity also supports sponsors.

By Production Stage Insights

The Drug Substance Manufacturing Segment Dominated the Market With 67% in 2025

The drug substance manufacturing segment held the largest revenue share of 67% of the biologics CDMO for mAB market in 2025, as large-scale cell culture and purification remained core outsourcing activities. Process optimization improved productivity. Additionally, according to the survey conducted by Payal Rabde, increased biologics approvals also sustained investments.

The drug product manufacturing segment held the second-largest share of 33% of the market in 2025 and is expected to grow with the fastest CAGR of 11.6% during the forecast period, as injectable formulation complexity increases outsourcing. Growth of ready-to-use delivery systems also supports their expansion. Integrated CDMO services also improve efficiency.

By End User Insights

The Large Biopharmaceutical Companies Segment Dominated the Market With 48% in 2025

The biopharmaceutical companies segment held a major revenue share of 48% of the biologics CDMO for mAB market in 2025 and was driven by large manufacturers outsourcing to expand capacity and reduce capital expenditure. Global commercialization required reliable supply chains, which increased their use. Strategic partnerships also remained strong.

The emerging biotech companies segment held the second-largest share of 34% of the market in 2025 and is expected to expand rapidly during the forecast period, due to venture funding accelerating biologics development. Small companies rely on CDMOs for manufacturing expertise. Asset-light operating models also encourage outsourcing.

By Indication Insights

The Oncology Segment Dominated the Market With 46% in 2025

The oncology segment contributed the biggest revenue share of 46% of the biologics CDMO for mAB market in 2025, as it remained the largest antibody development area. Continuous approvals also increased commercial manufacturing needs. Precision medicine also supported their innovation.

The infectious diseases segment held a share of 8% of the market in 2025 and is expected to gain the highest share during the forecast period, driven by emerging infectious threats stimulating antibody development. Government preparedness initiatives also increase investment. Rapid-response manufacturing is also gaining importance.

Regional Insights

The Market Across North America Driven by Strong Innovation Ecosystem

North America dominated the biologics CDMO for mAB market with 43% in 2025, due to a strong biologics innovation ecosystem, which supported outsourcing. Large CDMO presence also expanded manufacturing capacity, which increased their acceptance rate. High R&D spending also contributed to their sustained demand. Presence of advanced biomanufacturing infrastructure and favourable regulatory support also encouraged the use of biologics CDMOs. Growth in antibody-based drugs and biologics also increased their demand, which contributed to the market growth.

US Market Growth

U.S. held a 37% share of the biologics CDMO for mAB market in 2025, driven by the largest biologics manufacturing base. Extensive clinical development activity and continuous investments also expanded commercial production. Expansion in the mAb pipeline and bioprocessing technologies also increased the reliance on biologics CDMO services. Additionally, based on the information gathered by Payal Radbe, the presence of major companies such as Thermo Fisher Scientific Inc., with annual revenue over $45 billion, recently announced a quarterly cash dividend of $0.47 per common share, also enhanced the market expansion.

Canada Market Growth

Canada held a 4% share in the market in 2025 and is expected to grow with the highest CAGR of 10.80% during the studied years, due to government support strengthening biologics manufacturing. CDMO investments continue growing, which drives their expansion, where innovation clusters also expand their capacity. Strong government support and new collaborations are also increasing the use of biologics CDMO services for mAB production. Favorable regulatory support and an expanding biopharmaceutical sector also support their use.

Europe’s Market Gaining Momentum

Europe held a 29% share of the biologics CDMO for mAB market and is expected to grow significantly during the forecast period, due to the presence of a mature pharmaceutical industry that drives outsourcing. Strong regulatory expertise also supports biologics production, where expansion of commercial facilities continues. Expanding biologic and biosimilar pipelines also fuels the demand for biologics CDMOs, where increasing demand for personalized medicine is also promoting their use, enhancing the market growth.

Germany Market Growth

Germany held a 7% share in the biologics CDMO for mAB market in 2025, driven by the presence of leading biologics manufacturing infrastructure. Strong pharmaceutical investment and advanced process technologies also accelerated production, which increased the use of biologics CDMOs. Growth in strategic collaborations among the institutes and industries also increased their use, where advancements in next-generation antivirals also increased their use. Additionally, demand for advanced manufacturing technologies and personalized medicines also increased the dependence on CDMO services.

Switzerland Market Growth

Switzerland held a 4% share in the market in 2025 and is expected to witness the fastest growth with a CAGR of 10.90% over the forecast period, due to global pharmaceutical headquarters sustaining outsourcing demand. Advanced manufacturing technologies are also improving efficiency, where premium biologics production also expands the use of biologics CDMOs for mAB manufacturing and commercialization. Strong regulatory support and growing R&D activities across institutes are also leading to a rise in their collaboration to leverage various advanced technologies.

Asia Pacific Emerging as a High-Growth Market

Asia Pacific held a 21% share of the biologics CDMO for mAB market in 2025 and is expected to grow at the fastest CAGR during the forecast period, due to cost competitiveness and expanding CDMO capabilities, which are attracting global outsourcing. Growing government incentives also stimulate investments, where rapid biotechnology growth accelerates their demand. Increasing number of clinical trials and outsourcing trends are also increasing their use, where a rise in monoclonal antibody-based therapies is also promoting the market growth.

China Market Growth

China held a 9% share of the biologics CDMO for mAB market in 2025, driven by massive CDMO expansion, which strengthened global competitiveness. Domestic biologics innovations also increased their use, where commercial manufacturing capacity growth also increased the shift towards biologics CDMOs. Presence of affordable services, skilled personnel, and regulatory expertise also attracted companies. Growth in targeted therapies and complex biologics pipeline also increased their use.

India Market Growth

India held a 3% share in the market in 2025 and is expected to expand rapidly in the coming years, due to rapid CDMO expansion and a skilled workforce attracting international clients. Growing government support is also encouraging biologics manufacturing, where lower production costs also improve competitiveness. At the same time, the increasing chronic disease burden is also driving the demand for mAb therapies and biologics, which is increasing their production rates, promoting the reliance on CDMO services.

Expanding Local Manufacturing Propel Latin America’s Market

Latin America held a 4% share in the biologics CDMO for mAB market in 2025 and is expected to show lucrative growth during the forecast period, due to local biologics manufacturing developing steadily. Government healthcare investments are increasing, which supports the reliance on biologics CDMOs, where regional outsourcing opportunities are also expanding, promoting their use. Expanding healthcare infrastructure is also driving the adoption of various biologics and biosimilars, increasing the use of mAbs, leading to new CDMO collaborations. Additionally, growing adoption of advanced technologies is also increasing their operational efficiency, promoting market growth.

Brazil Market Growth

Brazil held a 2% share in the biologics CDMO for mAB market in 2025 and is expected to gain the highest market share with a CAGR of 10.20% during the forecast period, driven by the largest regional pharmaceutical market. Growth in public investments also supported biologics production, where local manufacturing capabilities also improved, which encouraged the use of biologics CDMOs. Based on Payal Rabde's analysis, the growing chronic disease burden is also driving the demand for mAB therapies, fueling the outsourcing trends and use of CDMO services.

The rest of Latin America held a 1% share in the market in 2025, due to healthcare modernization supporting biologics production. Increasing regional partnerships are also strengthening manufacturing capabilities, where growing outsourcing opportunities are also promoting the use of biologics CDMOs. A rise in government initiatives is also strengthening their use, where expanding healthcare infrastructure is also attracting companies. Growing investments in targeted therapies are also propelling their acceptance rates.

Government Strategies Boost MEA’s Market

MEA held a 3% share in the biologics CDMO for mAB market in 2025 and is expected to show notable growth during the forecast period, due to increasing government diversification strategies, which support biotechnology investments. Healthcare infrastructure is improving steadily, where growing international partnerships are also expanding manufacturing capabilities, attracting companies. A favourable regulatory framework and growing healthcare expenditures are also supporting biologics and mAB innovation, leading to a rise in reliance on CDMOs, enhancing market growth.

GCC Market Growth

GCC held a 1% share in the biologics CDMO for mAB market in 2025 and is expected to show the fastest growth with a CAGR of 11.20% over the forecast period, driven by growth in national biotechnology strategies, which encouraged investment. Local manufacturing capacity also increased, where healthcare spending remained strong, which increased the use of biologics CDMO for mAB. A rise in collaborations and healthcare investments also increased the use of CDMOs for advanced manufacturing technologies.

The rest of the Middle East & Africa held a 1% share in the market in 2025, due to emerging biotechnology initiatives attracting investment. Regional manufacturing infrastructure development and increasing demand for biologics also continue the use of CDMO services. According to the analysis of Payal Rabde, growing investment and favorable regulatory support also promote their use, where affordable services and expertise also increased their demand. A rise in patient population and outsourcing trends are also driving their expansion.

Top Vendors and Their Offerings

Latest Announcement by Industry Leader

In January 2026, after announcing the successful closure of the Asset Purchase Agreement, Share Purchase Agreement Zydus Lifesciences Limited offering advanced manufacturing facilities in the global biologics contract development and manufacturing organization ("CDMO") business, Dr. Garo Armen, Chairman and CEO of Agenus, Inc., stated that, "This collaboration unites Agenus' pioneering immunotherapy pipeline and U.S.-based clinical development capabilities with Zydus' global manufacturing, operational scale, and commercial infrastructure. The transaction allows Agenus to monetize manufacturing assets while securing dedicated, high-quality U.S. biologics capacity to support botensilimab and balstilimab. Importantly, it sharpens our focus on advancing BOT and BAL through late-stage development and expanding paid access to patients globally who have limited treatment options."

Recent Developments in the Market

• In June 2026, successful tech-transfer and manufacturing of the first commercial-scale GMP batches of Daretabart, which is a humanized monoclonal antibody targeting GD2 for high-risk neuroblastoma developed by Renaissance Pharma’s lead candidate, was announced by Aragen, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO). This anti-GD2 monoclonal antibody targeting high-risk neuroblastoma (HRNB), a rare pediatric cancer, was granted Fast Track Designation from the FDA in April 2026.
• In April 2025, to offer comprehensive services, deliver high-quality biologics to market, and reduce complexity, a collaboration was announced between Sartorius (CDMO) and Mabion S.A. In this collaboration, Sartorius will support lab-scale development with its proprietary cell culture media, expertise in cell line development and upstream process optimization, where Mabion will drive upstream processes.

Competitive Landscape

Competitive Positioning Matrix

Lonza Group, Samsung Biologics, and Wuxi Biologics led the market based on the competitive positioning matrix.

Market Share Analysis of Leading Companies

As per the market share analysis, Lonza Group, Samsung Biologics, and Wuxi Biologics were the leading companies.

Business Performance

Lonza Group, Samsung Biologics, and Wuxi Biologics registered their dominance over the market based on business performance.

Market Companies

Catalent biologics

Fujifilm Biotechnologies

Boehringer Ingelheim

Future Market Outlook and Strategic Forecast

Future Manufacturing Trends

The future manufacturing trends in biologics CDMO for the mAB market are driven by increasing use of single-use bioprocessing systems, implementation of continuous biomanufacturing, adoption of digital manufacturing technologies, and expanding global manufacturing networks.

Emerging Business Models

The emerging business models such as end-to-end, one-stop shop, platform technology, flexible manufacturing, and digital manufacturing technologies are expected to drive further opportunities.

Future Technology Adoption

Growing demand for high manufacturing efficiency, large-scale mAB manufacturing, real-time monitoring, faster development timelines, flexible manufacturing platforms, and sustainable manufacturing practices will fuel advanced technology adoption.

Expected Investment Hotspots

Areas with large-scale biologics manufacturing facilities, digital manufacturing platforms, high strategic partnerships, and a rise in next-generation mAB production are the expected investment hotspots.

Long-Term Commercial Opportunities

Expanding mAB pipeline, rise in next-generation antibodies R&D activities, demand for personalized medicines, advancements in biologics, and digital manufacturing technologies are some of the long-term commercial opportunities.

Strategic Recommendations for Industry Participants

Focus on next-generation biologics, digital manufacturing capabilities, continuous bioprocessing technologies, and sustainability are some of the key strategic recommendations for industry participants.

Analyst Opinion

As per Payal Rabde's analysis, the biologics CDMO for mAb market is anticipated to show significant growth during the forecast period, which will be driven by a wide range of factors. The growing outsourcing trends, chronic disease burden, rising demand for targeted therapies, advancements in cell & gene therapies, and expanding biologics pipelines will drive the demand for biologics CDMO for mAB production. Additionally, rapid healthcare digitization will support the adoption of advanced technologies, which will drive the expansion and advancements of CDMO facilities, leading to new collaborations. Moreover, segments such as bispecific monoclonal antibodies, clinical scale, and oncology are expected to show rapid growth, making them ideal for investments. Major industries like Lonza Group, Samsung Biologics, and Wuxi Biologics are expected to contribute actively to the market expansion, which will attract new investments.

Segments Covered in the Report

By Service Type

• Cell Line Development
  • Stable Cell Line Development
  • Expression Optimization
  • Clone Screening & Selection
• Process Development
  • Upstream Process Development
  • Downstream Process Development
  • Analytical Method Development
• GMP Manufacturing
  • Clinical Manufacturing
    • Phase II
    • Phase III
  • Commercial Manufacturing
• Fill-Finish Services
  • Vial Filling
  • Prefilled Syringes
  • Cartridges
• Analytical & Quality Control Testing
  • Method Validation
  • Stability Testing
  • Release Testing
  • Biosafety Testing
• Regulatory Support
  • CMC Documentation
  • Regulatory Submission Support
  • Quality Assurance & Compliance

By Molecule Type

• Conventional Monoclonal Antibodies
• Bispecific Monoclonal Antibodies
• Antibody Fragments
  • Fab
  • scFv
  • Nanobody
• Antibody-Drug Conjugate (mAb Component)

By Expression System

• CHO Cells
• NS0 Cells
• SP2/0 Cells
• HEK293 Cells
• Other Mammalian Cell Lines

By Manufacturing Scale

• Preclinical Scale
• Clinical Scale
• Commercial Scale

By Production Stage

• Drug Substance Manufacturing
• Drug Product Manufacturing

By End User

• Large Biopharmaceutical Companies
• Emerging Biotech Companies
• Virtual Biopharma Companies
• Academic & Research Institutes

By Indication

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Hematology
• Neurology
• Cardiovascular Diseases
• Metabolic Diseases
• Other Indications

By Region

• North America
  • U.S.
  • Canada 
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina 
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany
    • Italy 
    • France 
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland 
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan 
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries 
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait 
    • Oman 
    • Bahrain
  • South Africa 
  • Egypt 
  • Rest of MEA